AUM Biosciences will be attending the prestigious J.P. Morgan Healthcare Conference in San Francisco, California

San Francisco, 13-16 January 2020

AUM Biosciences has been invited to attend the 38th Annual J.P. Morgan Healthcare Conference taking place January 13th through 16th in San Francisco, California, USA.

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry. It brings together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community from around the world encompassing the entire global healthcare landscape.

AUM Biosciences is pleased to be a part of such a prestigious event and to be able to contribute to shaping the future discourse in global healthcare.

More information about the conference can be found here

For any additional queries, please contact

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit